Company: NCEL
Filing Date: 2025-03-03
Form Type: F-4/A
Source: 0001213900-25-018981
Chunk: 60

Company: NewcelX Ltd.
Filing Date: 2025-03-03
Form: F-4/A
Chunk 60
---
 number of shares of common stock in excess of the beneficial ownership limitation. As a result, the number of NLS Common Shares reflected in the table owned by Alpha Capital Anstalt includes (a) any outstanding NLS Common Shares held by such shareholder, and (b) if any, the number of preferred shares and warrants convertible into NLS Common Shares that the holder has the right to acquire within 60 days of February 27, 2025 without such holder or any of such holder’s affiliates beneficially owning more than the beneficial ownership limitation of 9.99%. The address for Alpha Capital Anstalt is Lettstrasse 32, Vaduz 9490, Liechtenstein. Nicola Feuerstein, a Director of Alpha Capital Anstalt, holds voting and dispositive power over the securities held by Alpha Capital Anstalt. At the Closing, 111,429 RSUs issued by Kadimastem are expected to be exchanged for 312,430 RSUs of the combined company, and 204,170 Kadimastem options to purchase Kadimastem Ordinary Shares are expected to be exchanged for 572,463 options to purchase NLS Common Shares of the combined company. Q. What is the anticipated ownership of options, warrants and other outstanding equity awards that are anticipated to remain outstanding following the completion of the Merger? As of February 28, 2025, the expected total amount of RSUs of Kadimastem that will be exchanged for RSUs of NLS is 111,429 RSUs of Kadimastem, which will equal to 312,430 RSUs of NLS at the Effective Time. All such RSUs have been and shall continue to be owned by current and past officers and employees of Kadimastem, and represent approximately 1.11% of the estimated number of issued and outstanding shares of the combined company immediately following the Closing. As of February 28, 2025, the total amount of Kadimastem options that will be exchanged for NLS options at the Effective Time will be 204,170, which will be exchanged for 572,463 NLS options. All such options have been and shall continue to be owned by current and past officers and employees of Kadimastem, and represent approximately 2.04% of the estimated number of issued and outstanding shares of the combined company immediately following the Closing. Q.Who can help answer my questions? With regard to the NLS Meeting, shareholders of NLS